Table 1

Patient’s characteristics

Patients’ characteristicsN=88
Median age, years (range)60 (27–91)
Gender: female/male, n (%)45 (51)/43(49)
Melanoma AJCC stage
 Stage IV, n (%)84 (96)
 Stage IIIC, n (%)3 (3)
 Stage IIIB, n (%)1 (1)
CNS metastases at baseline, n (%)25 (22)
BRAF status
 Wilde type, n (%)57 (65)
 Mutation, n (%)26 (29)
 NA, n (%)5 (6)
BMI
 Normal weight (18.5<BMI≤24.9), n (%)24 (27)
 Overweight (25<BMI≤29.9), n (%)36 (41)
 Obese (BMI ≥30), n (%)28 (32)
Line of treatment
 First-line treatment, n (%)55 (62,5)
 Second-line treatment, n (%)22 (25)
 Third-line treatment, n (%)10 (11,4)
 Fourth-line treatment, n (%)1 (1,1)
Response rate at 1° assessment
 Complete response, n (%)6 (7)
 Partial response, n (%)16 (18)
 Stable disease, n (%)30 (34)
 Progression disease, n (%)36 (41)
DCR44 (50)
ORR22 (25)
Nivolumab dosage
 Flat dose 240 mg, n (%)11 (12)
 Flat dose 480 mg, n (%)19 (22)
 Dose 3 mg/kg, n (%)58 (66)
LDH level
 High30 (34)
 Normal33 (38)
 NA25 (28)
  • AJCC, American Joint Commission on Cancer; BMI, body mass index; CNS, central nervous system; DCR, disease control rate; LDH, lactate dehydrogenase; NA, not available; ORR, overall response rate.